BuzzFeed (NASDAQ:BZFD) Azioni

BuzzFeed

BuzzFeed Inc is a tech-powered, diversified media company that reaches hundreds of millions globally through its cross-platform news and entertainment network. The company produces articles, lists, quizzes, videos, and original series; lifestyle content through brands including Tasty, social food network; original reporting and investigative journalism through BuzzFeed News and HuffPost; an industry- affiliate business, strategic partnerships, licensing and product development through BuzzFeed Commerce; and original productions across broadcast, cable, SVOD, film and digital platforms for BuzzFeed Studios.

BuzzFeed Inc

The Board of Directors of The Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) declared an increased quarterly dividend of $1.0568 per share on the Common Stock and on the Series A and Series B ESOP Convertible Class A Preferred Stock of the Company, payable on or after May 15, 2025 to Common Stock shareowners of record at the close of business on April 21, 2025, and to Series A and Series B ESOP Convertible Class A Preferred Stock shareowners of record at the start of business on April 21, 2025. This represents a five percent increase compared to the prior quarterly dividend.
P&amp;G has been paying a dividend for 135 consecutive years since its incorporation in 1890 and has increased its dividend for 69 consecutive years. This reinforces our commitment to return cash to shareowners, many of whom rely on the steady, reliable income earned with their investment in P&amp;G.

News

Dividends

P & G Announces Quarterly Dividend Increase Of $1.0568 Per Share

Contracts

SATL

Satellogic Awarded $30M Multi-Year Contract To Provide Ultra-Low Latency Analytics To A Defense And Security Customer

Deep-pocketed investors have adopted a bullish approach towards Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in SCHW usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Charles Schwab. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 62% leaning bullish and 37% bearish. Among these notable options, 6 are puts, totaling $406,855, and 2 are calls, amounting to $64,485.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $65.0 to $82.5 for Charles Schwab over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Charles Schwab stands at 3443.86, with a total volume reaching 1,133.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Charles Schwab, situated within the strike price corridor from $65.0 to $82.5, throughout the last 30 days.
<h3>Charles Schwab 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744143333_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCHW</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$4.95</td>
<td>$4.7</td>
<td>$4.9</td>
<td>$65.00</td>
<td>$85.7K</td>
<td>4.5K</td>
<td align="right">175</td>
</tr>
<tr>
<td>SCHW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$5.2</td>
<td>$4.85</td>
<td>$4.85</td>
<td>$65.00</td>
<td>$85.3K</td>
<td>4.5K</td>
<td align="right">351</td>
</tr>
<tr>
<td>SCHW</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$7.8</td>
<td>$7.65</td>
<td>$7.8</td>
<td>$67.50</td>
<td>$78.0K</td>
<td>2.6K</td>
<td align="right">278</td>
</tr>
<tr>
<td>SCHW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$4.4</td>
<td>$4.35</td>
<td>$4.35</td>
<td>$72.50</td>
<td>$72.6K</td>
<td>2.4K</td>
<td align="right">22</td>
</tr>
<tr>
<td>SCHW</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$2.14</td>
<td>$1.95</td>
<td>$2.0</td>
<td>$65.00</td>
<td>$49.6K</td>
<td>9.2K</td>
<td align="right">6</td>
</tr>
</tbody>
</table>

<h3>About Charles Schwab</h3>
Charles Schwab operates in brokerage, wealth management, banking, and asset management. It runs a large network of brick-and-mortar brokerage branch offices and a well-established online investing website, and it has mobile trading capabilities. It also operates a bank and a proprietary asset-management business and offers services to independent investment advisors. Schwab is among the largest firms in the investment business, with over $10 trillion of client assets at the end of 2024. Nearly all of its revenue is from the United States.
In light of the recent options history for Charles Schwab, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Charles Schwab Standing Right Now?</h3>
<ul>
<li>With a volume of 18,447,027, the price of SCHW is down -0.16% at $69.93. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 9 days.</li>
</ul>
<h3>What The Experts Say On Charles Schwab</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $86.2.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from JMP Securities keeps a Market Outperform rating on Charles Schwab with a target price of $94. 
&#x2A; An analyst from Piper Sandler persists with their Neutral rating on Charles Schwab, maintaining a target price of $74. 
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on Charles Schwab, which currently sits at a price target of $84. 
&#x2A; In a cautious move, an analyst from JMP Securities downgraded its rating to Market Outperform, setting a price target of $94. 
&#x2A; An analyst from Truist Securities has decided to maintain their Buy rating on Charles Schwab, which currently sits at a price target of $85. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Charles Schwab with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

Markets

SCHW

A Closer Look at Charles Schwab's Options Market Dynamics

Citigroup analyst Paul Lejuez maintains Urban Outfitters (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) with a Buy and lowers the price target from $65 to $54.

Price Target

Analyst Ratings

URBN

Citigroup Maintains Buy on Urban Outfitters, Lowers Price Target to $54

CPNG

Coupang Acquires Greenoaks Equity Interest In Surpique LP; Pays $140.1M To Greenoaks For Surpique LP Interest

Fiscal 2025 Financial Guidance:
For the fiscal year ending May 30, 2025, Aehr is temporarily withdrawing its guidance due to ongoing tariff uncertainty.

Guidance

AEHR

Aehr Says For The Fiscal Year Ending May 30, 2025, The Co Is Temporarily Withdrawing Its Guidance Due To Ongoing Tariff Uncertainty

Aehr Test Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHR#NASDAQ">AEHR</a>) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $0.04 by 75 percent. This is a 333.33 percent increase over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $18.31 million which beat the analyst consensus estimate of $17.76 million by 3.07 percent. This is a 142.06 percent increase over sales of $7.56 million the same period last year.

Earnings

Earnings Beats

Aehr Test Systems Q3 Adj $0.07 Beats $0.04 Estimate, Sales $18.31M Beat $17.76M Estimate

Citigroup analyst Paul Lejuez maintains Gap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) with a Buy and lowers the price target from $32 to $22.

Citigroup Maintains Buy on Gap, Lowers Price Target to $22

WIIM

ANNX

Annexon shares are trading higher after the company announced the presentation of data for its late-stage targeted therapy for GBS at the AAN Annual Meeting.

Citigroup analyst Paul Lejuez maintains Abercrombie &amp; Fitch (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) with a Buy and lowers the price target from $135 to $98.

Citigroup Maintains Buy on Abercrombie & Fitch, Lowers Price Target to $98

Management

General

NMRK

Newmark Group Names Lou Alvarado As COO

Karman Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRMN#NYSE">KRMN</a>) reported quarterly earnings of $0.08 per share. This is a 166.67 percent increase over earnings of $0.03 per share from the same period last year. The company reported $345.25 million in sales this quarter. This is a 37.71 percent increase over sales of $250.71 million the same period last year.

KRMN

Karman Holdings FY EPS $0.08 Up From $0.03 YoY, Sales $345.25M Up From $250.71M YoY

Onestream Co-Founder Craig Colby To Transition To Chief Success Officer Effective May 1, 2025 ;Thomas Shea To Assume Role Of President

NTHI

NeOnc Technologies shares are trading higher after the company announced near full enrollment for its Phase 1 clinical trial of NEO212 for brain cancer

- ImmuCell Corporation (Nasdaq:&nbsp;ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today&nbsp;announced preliminary, unaudited sales results for the first quarter of 2025.
Since the first quarter of 2020, the Company has been providing a preliminary look at its unaudited top line results soon after the close of the quarter. The Company expects to continue providing this prompt, preliminary report on product sales until further notice going forward.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="5">Preliminary, Unaudited Total Sales Results: &nbsp;</td>
</tr>
<tr>
<td>2025</td>
<td>2024</td>
<td>$ Increase</td>
<td>% Increase</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>During the Three-Month Periods Ended March 31,</td>
<td>$8.1 million</td>
<td>$7.3 million</td>
<td>$0.8 million</td>
<td>11%</td>
</tr>
<tr>
<td>During the Six-Month Periods Ended March 31,</td>
<td>$15.8 million</td>
<td>$12.4 million</td>
<td>$3.5 million</td>
<td>28%</td>
</tr>
<tr>
<td>During the Twelve-Month Periods Ended March 31,</td>
<td>$27.3 million</td>
<td>$21.3 million</td>
<td>$6.0 million</td>
<td>28%</td>
</tr>
</tbody>
</table>
</figure>
 During the first quarter of 2025, the Company recorded its all-time quarterly sales record, exceeding the previous all-time high mark set during the fourth quarter of 2024 by 4%. The strong sales during the first quarter of 2025 helped, in part, reduce the backlog of orders to $4.0 million as of March 31, 2025, from $4.4 million as of December 31, 2024. Sales recorded during both the six-month and twelve-month periods ended March 31, 2025 also set all-time records for those periods.

ICCC

ImmuCell Preliminary Q1 2025 Revenue Of $8.1M Up From $7.3M YoY; Reduced The Backlog Of Orders To $4M As Of March 31, 2025, From $4.4M As Of December 31, 2024

Maxim Group analyst Anthony Vendetti maintains Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) with a Buy and raises the price target from $75 to $100.

NUTX

Maxim Group Maintains Buy on Nutex Health, Raises Price Target to $100

Mama`s Creations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAMA#NASDAQ">MAMA</a>) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $0.03 by 33.33 percent. This is unchanged from the same period last year. The company reported quarterly sales of $33.585 million which beat the analyst consensus estimate of $31.019 million by 8.27 percent. This is a 25.79 percent increase over sales of $26.700 million the same period last year.

MAMA

Mama's Creations Q4 2025 GAAP EPS $0.04 Beats $0.03 Estimate, Sales $33.585M Beat $31.019M Estimate

SAN MATEO, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=pRSoJS4egi5AoUvSmziXfzPTtM5867S_AYz5wh1jl-8Ed1C7_ZCqcFQS1o-NHlC0BB-egWkIvME-MZkyB4-OdDCBDAlrEzs49Q1A03dXhe0=">Vincerx Pharma, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) today announced that it has terminated the previously announced non-binding Letter of Intent (LOI) with Global Digital Holdings Inc., conducting business as QumulusAI, regarding a potential merger.
Following this decision, the Company's board of directors has authorized management to initiate wind-down activities and continue exploring monetization of assets and out-licensing opportunities.
"I want to express our deepest gratitude to the investigators, patients, employees, and partners who have supported Vincerx's mission," said Raquel Izumi, Ph.D., Acting Chief Executive Officer of Vincerx. "Your contributions have meant everything. Although unprecedented, adverse market dynamics prevented us from continuing the development of our programs, numerous patients with cancer—who had few therapeutic options—benefited from our therapies in the Phase 1 trials. For the chance you gave us to help those patients, we thank you."

Biotech

VINC

Vincerx Pharma Announces That It Has Terminated Previously Announced Non-Binding Letter Of Intent With Global Digital Holdings Regarding a Potential Merger

KRUS

Kura Sushi Sees FY25 Total Sales $275M-$279M vs $280.741M Est.

Oral Presentation Features Phase 3 Data Showing Rapid Recovery and Durable Benefit of Tanruprubart (formerly ANX005) on Clinically Meaningful Measures across Multiple Stages of GBS
Disease Education Campaign for Healthcare Providers called Move GBS Forward&#x2122; (<a href="https://www.globenewswire.com/Tracker?data=996SrP35r5vecT4gO1dn68T7-NUePhl8XXimJCcRwHmCgkXYb0D_5SQ1SsEFLJkdNq8q4igwk-1VFjEcxkDRtPgrMoYS0mAc08SQbfXVaWs=">MoveGBSForward.com</a>) Highlights Life-altering Impact of GBS
BRISBANE, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=3aoQCjRMWzRCgOmEo2VMp7KZ5bz50dvEQZZc3CljQEL32ZpiRTVtfGcAVUmhmNrMweg52XAredlaKWzePcpVeA==">Annexon, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANNX#NASDAQ">ANNX</a>), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today presented data for its late-stage targeted therapy for GBS and showcased new disease education activities at the AAN Annual Meeting taking place April 5–9, 2025, in San Diego, California. An <a href="https://www.globenewswire.com/Tracker?data=aRK4M6Fm8iHnB2a1F_IqhDFZZgvGOI3PzKfCkaEzZVQIxvjAPAeUOzYjqm2ClGMZIthaGuevZBoKBoRM0OsnrbZoxJHLS9NSkpRt_D3yUkr3McPHK3viehUrMGAOV9qc0FMQfXxvTx3Cis7CKF1AudOFgNeXgX2SwZBhw_cAAXaqY2vVRsUMJUtxmZxBWno8">oral presentation today during the "Clinical Trials Plenary" session</a> featured results of the tanruprubart (formerly ANX005) Phase 3 placebo-controlled trial reinforcing its rapid and durable clinical benefits for patients with GBS. A replay of the session is available to AAN registrants.
GBS is a neuromuscular emergency that affects at least 150,000 people worldwide each year, with&nbsp;no FDA-approved therapies. The rare autoimmune disease is characterized by rapidly progressing and severe weakness that can lead to complete paralysis, often requiring intensive care and mechanical ventilation.
Tanruprubart is a first-in-kind monoclonal antibody designed to block C1q, the initiating molecule of the classical complement cascade. With a single infusion, tanruprubart halts ongoing neuroinflammation and nerve damage in the acute phase of GBS to improve and expedite overall recovery.

Annexon To Present Pivotal Data On First Potential Targeted Therapy For Guillain-Barré Syndrome And Showcases New GBS Education Campaign At AAN 2025 Annual Meeting

Press Releases

BuzzFeed, Inc. First Quarter 2024 Financial Results in Line With March Outlook

BuzzFeed Inc., Bullish About Future of the Company, Redefines Compensation Model to Drive Value Creation

BuzzFeed, Inc. to Release Second Quarter 2024 Financial Results on Monday, August 12, 2024

BuzzFeed, Inc. Posts Strong Q2 Financial Results and Expects Continued Improvement in Q3

BuzzFeed, Inc. to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

BuzzFeed, Inc. Delivers Strong Q3 Financial Results

BuzzFeed, Inc. Announces Sale of First We Feast to an Affiliate of Soros Fund Management in $82.5 Million All-Cash Deal

BuzzFeed Declares War on "SNARF" and Announces a New Social Platform

BuzzFeed, Inc. Completes Strategic and Organizational Changes Following a Transformative 2024

Fintech

Real Estate

Fathom Holdings Appoints Highly Experienced Technology Industry Expert Adam Rothstein to Board of Directors

BZFD

FTHM

RSVR

The Arena Group Holdings, Inc. Common Stock

Arena Group Holdings

Bumble

Cheer Holding, Inc. - Class A Ordinary Share

Cheer Holding

DHI Group

Fangdd Network Group Ltd. - Class A Ordinary Shares

Fangdd Network Group

Phoenix New Media Limited American Depositary Shares, each representing 48 Class A ordinary shares.

Phoenix New Media

Giftify

HWH International

Intelligent Protection Management Corp. - Common Stock

Intelligent Protection

IZEA Worldwide

36Kr Holdings Inc. - American Depositary Shares

36KR Holdings

MediaAlpha

MoneyHero Limited - Class A Ordinary Shares

MoneyHero

Outbrain

Oriental Culture Holding LTD - Ordinary Shares

Oriental Culture Holding

PSQ Holdings

System1

So-Young International Inc. - American Depository Shares

So-Young Intl

TrueCar

trivago N.V. - American Depositary Shares

trivago

Travelzoo

Zedge

Zhihu Inc. American Depositary Shares, each representing three (3) Class A Ordinary Shares

Comments

BuzzFeed

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO